Original Publication Date: 1 April, 2016
Publication / Source: CNS Oncology
Authors: Victor A Levin
The latest catch phrase in cancer medicine is ‘personalized medicine’ denoting the potential to devise and prescribe therapies based on molecular and genetic information quasi-unique to the patient and the patient’s tumor as well as therapies developed using cell line or rodent tumor model screens of drug candidates [1–8]. The molecular–genetic approach has the potential of being far more informative than the high-throughput cell line and/or rodent tumor model approach for a number of reasons.